Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2015-07-13. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
Follow-Up Questions
Qui est le CEO de Medicenna Therapeutics Corp ?
Dr. Fahar Merchant est le Chairman of the Board de Medicenna Therapeutics Corp, il a rejoint l'entreprise depuis 2011.
Quelle est la performance du prix de l'action MDNAF ?
Le prix actuel de MDNAF est de $0.7268, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Medicenna Therapeutics Corp ?
Medicenna Therapeutics Corp appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Medicenna Therapeutics Corp ?
La capitalisation boursière actuelle de Medicenna Therapeutics Corp est de $60.6M
Est-ce que Medicenna Therapeutics Corp est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 5 analystes ont établi des notations d'analystes pour Medicenna Therapeutics Corp, y compris 2 achat fort, 5 achat, 1 maintien, 0 vente et 2 vente forte
